Retrospective real-world research study on multiple myeloma therapy in China
| CONTEXT: This abstract with reference to full article originally published in Leuk Lymphoma Journal is a retrospective analysis of newly diagnosed multiple myeloma (MM) patients in China. The study looked at patients with and with high-risk cytogenetic abnormalities. Unsurprisingly the high risk group showed lower overall survival warranting more effective therapies for this group of patients. READ TIME: 1 min 1. “We defined a standard-risk group by the absence of HRCA, an intermediate-risk group with one HRCA, and a high-risk (HiR) group with at least two HRCAs.” 2. “This article was originally published here. We retrospectively studied the impact of cytogenetic abnormalities in 328 consecutive newly diagnosed multiple myeloma (MM) patients.” 3. “High-risk cytogenetic abnormalities (HRCAs) included del (17p), amp/gain (1q21), t(4;14), and t(14;16).” 4. “The HiR group constituted 14.3% of patients and was associated with a median overall survival (OS) of 28.6 months and progression-free survival (PFS) of 14.0 months.” 5. “Moreover, the HiR group predicted poor outcomes for OS and PFS in multivariate analyses, and bortezomib prolongation to nine cycles could not bring additional benefit to this entity, suggesting the necessity of more effective therapies for these patients.” Source URL:https://pubmed.ncbi.nlm.nih.gov/34219587/  |